An AI Platform integrating imaging data and models, supporting precision care through prostate cancer’s continuum
Editorial by Βy Prof. Daniele Regge, Chief of the Radiology Unit, Candiolo Cancer Institute (FPO) The Clinical Vision of the project and added value for patients One man in eight is diagnosed with prostate cancer during his lifetime and among them, approximately one...
By Prof Mu Koh, Royal Marsden NHS Foundation Trust (ICR) Primary prostate cancer is a heterogeneous disease in terms of disease aggressiveness and long-term outcomes. Many men who are diagnosed with prostate cancer will have indolent disease and die of other causes....
By Prof Jurgen Futterer & Prof Henkjan Huisman, RadboudUMC (RUN) Professors Jurgen Futterer and Henkjan Huisman are both affiliated with Radboudumc, Nijmegen, The Netherlands. They have a long-standing collaboration and are part of the EU H2020 project ProCAncer-I...
By Joao Correia, Innovation Manager at Biotronics3D Limited (B3D) The ProCAncer-I eCRF (electronic case report form) and Data Upload Tools support ProCAncer-I clinical partners in the process of compiling the required information and follow the defined protocols for...
By Theresa Henne, University of Vienna (UNIVIE), Clara Saillant University of Vienna (UNIVIE) &Varvara Kalokyri, Foundation for Research and Technology (FORTH) Data is increasingly regarded as a valuable resource, in particular for the development of Big Data and...
Biotronics3D was established in 2004 in London, opened an R&D Centre in Cambridge in 2009, opened a Central European Operations office in Bucharest in 2014, and established its Innovation Centre in Edinburgh during 2017. Biotronics3D recently integrated the...
The Girona Biomedical Research Institute (IDIBGI) aims to promote translational research to improve people's health. Located in Girona area, in Catalonia (Spain), its activity aims to increase knowledge of numerous diseases to improve their diagnosis, treatment and...
Newsletter #4 Contents
Prostate cancer can vary greatly in how aggressive it is, and knowing this in advance helps doctors decide the best course of treatment. Magnetic resonance imaging (MRI) is often used to detect prostate cancer, but figuring out just how aggressive the cancer is...
We are delighted to invite you to our session, “ProCAncer-I: An AI Platform Integrating Multiparametric MRI and AI Models”, at the European Congress of Radiology (ECR) 2025. Date: 26 February 2025 Time: 15:00 – 16:00 Location: ECR 2025, Vienna, Austria (conference...
ProCAncer-I will organise a Dedicated Session on the project during the European Congress of Radiology 2025 on the 26th of February 2025, at 15.00-16.00, with the title "ProCAncer-I: an AI platform integrating multiparametric MRI and AI models" where we will present...
Harnessing Big Data for the Future of Healthcare: Innovative Solutions with EUCAIM, ProCAncer-I, and European Health Data Spaces